Abstract Details

Title Treatment Experience, Burden, and Unmet Needs in Multiple Sclerosis Study: The Costs of MS Patients in Argentina

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 204

Objective

Background BACKGROUND: Multiple sclerosis (MS) is a common neurological disease among young adults in Argentina. It is known that the cost of the disease is higher but no studies up to date have measured the cost imposed by MS on the Argentinean health system and society.

Design/Methods DESIGN/METHODS: Subjects enrolled in the ENCOMS study were included. The study was a cross sectional study that included MS patients from 21 MS centers from 12 cities of Argentina developed to capture information on demographics, disease characteristics, severity, co morbidities, relapses as well as resource consumption and patient reported outcomes (PRO) associated with MS. Patients were stratified according to disease severity using EDSS (group 1 with EDSS between 0 and 3; group 2 with EDSS >3 and <7; group 3 with EDSS ?7) for the analysis. Costs were obtained from public resources for the second trimester of 2012 and converted to USD.

Results RESULTS: 266 patients were included. 87.6 % of patients were RRMS, 7.1% SPMS and 5.3 % PPMS. 70.7% of patients have an EDSS score between 0 and 3; 19.2% an EDSS >3 and <7 and 10.1% and EDSS ?7. Mean cost per year of patients with an EDSS between 0-3 was USD 36,025 (95% CI 31,985-38,068); for patients with EDSS > 3 and <7 was USD 40,705 (95% CI 37,199-46,300) and for patients with EDSS ?7 was USD 50,712 (95% CI 47,825-62,104). The mean cost per patient per year increased with worsening disability due to an increment on indirect cost.

Conclusions CONCLUSIONS: This is the first study performed in Argentina that evaluated the cost of MS considering disease severity. This information provides important data for the economic analysis of the disease Argentina, where this type of information is needed.

Authors/Disclosures
Celica Ysrraelit PRESENTER	Celica Ysrraelit has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Celica Ysrraelit has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Merck, . Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Biogen. Celica Ysrraelit has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Bayer. Celica Ysrraelit has received research support from Novartis. The institution of Celica Ysrraelit has received research support from ROCHE. The institution of Celica Ysrraelit has received research support from Roche.
	No disclosure on file
Andres M. Villa, MD (Hospital Ramos Mejia)	Dr. Villa has nothing to disclose.
Marcela Parada Marcilla, MD (Merck Serono Argentina)	No disclosure on file
Mario O. Melcom, MD (Lebensohn 115)	No disclosure on file
	No disclosure on file
Juan Ignacio Rojas, MD (Hospital Italiano)	Dr. Rojas has nothing to disclose.
	No disclosure on file
Gustavo Seifer, Prof	Gustavo Seifer, Prof has received personal compensation for serving as an employee of Novartis.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Rocco Totaro, MD (Clinica Neurologica Università degli Studi de)	No disclosure on file

��ɫ��

��ɫ��